JAZZ - Jazz Pharmaceuticals plc
175.87 -0.18 (-0.11%)
After hours: 4:05PM EDT
| Previous Close | 175.60 |
| Open | 175.76 |
| Bid | 161.53 x 800 |
| Ask | 187.50 x 800 |
| Day's Range | 174.51 - 176.41 |
| 52 Week Range | 128.58 - 184.00 |
| Volume | 291,792 |
| Avg. Volume | 577,595 |
| Market Cap | 10.613B |
| Beta | 1.36 |
| PE Ratio (TTM) | 24.11 |
| EPS (TTM) | 7.30 |
| Earnings Date | Aug 6, 2018 - Aug 10, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 190.30 |
- ACCESSWIRE•9 hours ago
Free Daily Technical Summary Reports on Iovance Biotherapeutics and Three Other Biotech Stocks
LONDON, UK / ACCESSWIRE / July 18, 2018 / If you want a free Stock Review on IOVA sign up now at www.wallstequities.com/registration. Gains were broad based as six out of nine sectors finished the trading session in green. WallStEquities.com has initiated research reports on the following Biotechnology stocks: GlycoMimetics Inc. (NASDAQ: GLYC), Iovance Biotherapeutics Inc. (NASDAQ: IOVA), Jaguar Health Inc. (NASDAQ: JAGX), and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ).
Markit•yesterdaySee what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- Reuters•5 days ago
U.S. court denies Jazz Pharma bid to revive narcolepsy drug patents
A U.S. appeals court on Friday ruled invalid patents owned by Jazz Pharmaceuticals PLC covering its narcolepsy drug Xyrem, giving Amneal Pharmaceuticals Inc a boost in its effort to launch a generic version of the medicine. The U.S. Court of Appeals for the Federal Circuit affirmed a series of rulings in favor of Amneal that the Jazz patents described obvious ideas. Shares of Jazz fell 2.5 percent to $175 in morning trading, while Amneal was up 1 percent to $18.50.
- Benzinga•7 days ago
Morgan Stanley Downgrades Jazz Pharmaceuticals As Stock Approaches Price Target
Morgan Stanley analyst wants to move to the sidelines on Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) as the stock has gained around 34 percent year-to-date and approached his price target of $183. The Analyst ...
- InvestorPlace•9 days ago
5 Low Price-to-Book Stocks Worth Buying in July
When evaluating a company’s value, investors mostly look at a stock’s Price-to-earnings (P/E) or Price-to-Sales (P/S) ratio. While P/E is the ratio of annual earnings to stock price, P/S reflects the amount investors pay for each dollar of revenues generated by the company.Source: Birthday Wishes
Markit•11 days agoSee what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Market Realist•12 days agoThese Could Be Jazz Pharmaceuticals’ Long-Term Growth Drivers
In June, the FDA accepted Jazz Pharmaceuticals’ (JAZZ) supplemental new drug application (or sNDA) for the label expansion of Xyrem. Jazz Pharmaceuticals filed an sNDA for the label expansion of Xyrem for the inclusion of its use in the treatment of cataplexy and EDS (excessive daytime sleepiness) in pediatric narcolepsy patients. Jazz Pharmaceuticals’ sNDA was supported by data from the Phase 2/3 EXPRESS trial, which was conducted on pediatric patients between seven and 17 years old with narcolepsy.
Market Realist•12 days agoHow Jazz Pharmaceuticals Is Positioned before Its Q2 2018 Results
Jazz Pharmaceuticals (JAZZ) generated revenue of $444.6 million in the first quarter, reflecting an ~18% YoY (year-over-year) rise. Xyrem and Vyxeos primarily pushed the company’s revenue growth in the quarter.
- Zacks•12 days ago
Dermira (DERM) Gains 5% in a Week, Post-Qbrexa Approval
Shares of Dermira, Inc. (DERM) increase about 5% after the FDA approved its excessive underarm sweating drug, Qbrexza.
Market Realist•12 days agoAnalysts Are Mostly Positive on Jazz Pharmaceuticals in July
In June, Jazz Pharmaceuticals (JAZZ) entered into an agreement with TerSera Therapeutics to sell its rights associated with Prialt to TerSera. As per the terms of the agreement, TerSera will provide employment opportunities to the majority of the Jazz Pharmaceuticals’ employees associated with Prialt. Presently, Prialt is the only therapy approved by the FDA for the treatment of chronic pain in adult individuals in need of intrathecal therapy.
- Zacks•12 days ago
Aclaris Stock Up on JAK Inhibitor's Encouraging Activity
Aclaris Therapeutics (ACRS) posts positive interim data from a phase II study on its Alopecia Areata candidate, ATI-502.
Markit•15 days agoSee what the IHS Markit Score report has to say about Jazz Pharmaceuticals PLC.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- Zacks•16 days ago
Jazz Sells Pain Drug Prialt's Rights to TerSera Therapeutics
Jazz Pharmaceuticals (JAZZ) signs a definitive contract to sell its Prialt rights to TerSera Therapeutics for a settled amount of $80 million in cash upon its closure.
- PR Newswire•19 days ago
Jazz Pharmaceuticals Enters Into Agreement with TerSera Therapeutics LLC for Prialt
DUBLIN, June 29, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced a definitive agreement to sell its rights related to Prialt® (ziconotide) intrathecal infusion to TerSera Therapeutics LLC (TerSera) for $80 million in cash at closing. The transaction is expected to close in the third quarter of 2018 and is subject to the satisfaction of customary closing conditions. As part of the transaction, TerSera will offer employment positions to a majority of the Jazz employees dedicated to Prialt.
- Zacks•19 days ago
5 Stocks Near 52-Week High: Is More Upside in the Cards?
Here are some stocks trading near their 52-week high levels with potential to scale higher.
- PR Newswire•19 days ago
Vyxeos™ Receives Positive CHMP Opinion for Treatment of Certain Types of High-Risk Acute Myeloid Leukaemia
DUBLIN, June 29, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending marketing authorisation of Vyxeos™ 44 mg/100 mg powder for concentrate for solution for infusion for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). Vyxeos is an advanced liposomal formulation that delivers a fixed-ratio (1:5) of daunorubicin and cytarabine. The Marketing Authorisation Application (MAA) for Vyxeos includes clinical data from five studies, including the pivotal Phase 3 study.
- Zacks•20 days ago
Jazz Pharmaceuticals' sNDA for Xyrem Gets Priority Review
Jazz Pharmaceuticals' (JAZZ) label expansion application for Xyrem in pediatric patients gets priority review from the FDA.
- PR Newswire•21 days ago
Jazz Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for Xyrem® (sodium oxybate) to Treat Cataplexy and Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients
DUBLIN, June 27, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced that the U.S. Food and Drug Administration (FDA) accepted for priority review its supplemental new drug application (sNDA) seeking revised labeling for Xyrem® (sodium oxybate) oral solution, CIII, to include an indication to treat cataplexy and excessive daytime sleepiness (EDS) in pediatric narcolepsy patients. The Prescription Drug User Fee Act (PDUFA) goal date for an FDA decision is October 27, 2018.
- Simply Wall St.•22 days ago
Innoviva And Other Great Growth Stocks
Analysts are bullish on these following companies: Innoviva, Jazz Pharmaceuticals, Cardlytics. These companies are relatively strong financially, and have a great outlook in terms of profits and cash flow. AnalysingRead More...
- Simply Wall St.•23 days ago
Is Jazz Pharmaceuticals plc’s (NASDAQ:JAZZ) Balance Sheet A Threat To Its Future?
There are a number of reasons that attract investors towards large-cap companies such as Jazz Pharmaceuticals plc (NASDAQ:JAZZ), with a market cap of US$10.76b. Doing business globally, large caps tendRead More...
- Zacks•29 days ago
5 Low-Beta Stocks to Buy as Trade Conflict Intensifies
Since trade tensions could drastically dent investor confidence, picking value stocks with low-beta looks like a smart option at this point.
- Zacks•last month
Zacks.com highlights: Jazz Pharmaceuticals, Baxter International, Boise Cascade, Insight Enterprises and Comfort Systems USA
Zacks.com highlights: Jazz Pharmaceuticals, Baxter International, Boise Cascade, Insight Enterprises and Comfort Systems USA
- Zacks•last month
5 Stocks Near 52-Week High With More Room to Run
Here are some stocks trading near their 52-week high levels and still with plenty of room for upside.
- Zacks•last month
5 Best Bargain PEG Stocks That Value Investors Love
While P/E alone fails to identify a true value stock, PEG helps to find the intrinsic value of a stock.
- ACCESSWIRE•last month
Iovance Biotherapeutics and Three Additional Biotech Stocks on Our Research Desk's Radar
Stock Research Monitor: JAGX, JAZZ, and LJPC LONDON, UK / ACCESSWIRE / June 15, 2018 / If you want a free Stock Review on IOVA sign up now at www.wallstequities.com/registration . On Thursday, June 14, ...
